| Checkpoint Kinase 2 (CHEK2) | |
|---|---|
| Gene | [CHEK2](/genes/chek2) |
| UniProt | O96017 |
| Molecular Weight | 60 kDa (543 amino acids) |
| Localization | Nucleus, cytoplasm |
| Family | Serine/Threonine protein kinase (CMGC family) |
| Chromosome | 22q12.1 |
| Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Li-Fraumeni Syndrome, Cancer |
Checkpoint Kinase 2 (CHEK2) is a serine/threonine kinase that plays a central role in the cellular response to DNA damage. As a key effector of the ATM-p53 DNA damage response pathway, CHEK2 coordinates cell cycle arrest, DNA repair, and apoptosis to maintain genomic integrity. Originally identified as a tumor suppressor frequently mutated in Li-Fraumeni syndrome and various cancers, CHEK2 has more recently been implicated in neurodegenerative diseases, where its role in the DNA damage response intersects with the pathological processes underlying Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions [1][2][3].
The importance of CHEK2 in post-mitotic neurons is particularly notable, as these cells must maintain genomic stability throughout decades of life without the option of cell division. The accumulation of DNA damage with aging, combined with the high metabolic demands of neurons, creates a context where CHEK2-mediated DNA repair is essential for neuronal survival [4].
CHEK2 is a 543 amino acid serine/threonine protein kinase with a modular structure that enables its diverse functions in the DNA damage response [1:1][5]:
CHEK2 is activated by phosphorylation in response to DNA double-strand breaks. ATM phosphorylates CHEK2 at threonine 68 (T68) within the SCD, triggering autophosphorylation at multiple sites (T383, T387, S516) and dimerization that results in full kinase activity. This activation cascade is essential for CHEK2's downstream phosphorylation of key substrates including p53, CDC25A, CDC25C, and BRCA1 [6][7].
The primary function of CHEK2 is to coordinate the cellular response to genotoxic stress [1:2][8][9]:
Cell cycle arrest: CHEK2 phosphorylates CDC25 phosphatases, leading to inhibition of CDK activity and cell cycle arrest at G1/S, S, and G2/M checkpoints, allowing time for DNA repair.
DNA repair: CHEK2 phosphorylates proteins involved in homologous recombination (HR) and non-homologous end joining (NHEJ), enhancing DNA repair capacity.
Apoptosis: Through phosphorylation of p53 at serine 20, CHEK2 promotes p53-mediated transcription of pro-apoptotic genes when DNA damage is irreparable.
Cellular senescence: CHEK2 contributes to the establishment of cellular senescence, a permanent cell cycle arrest that prevents the proliferation of damaged cells.
CHEK2 functions as a classical tumor suppressor gene. Loss-of-function mutations predispose to Li-Fraumeni syndrome and sporadic cancers of the breast, prostate, colon, and other tissues. Mouse models demonstrate that Chek2 deletion increases tumor susceptibility, while restoration of wild-type CHEK2 suppresses tumor growth [2:1][10][11].
The aging brain accumulates DNA damage from multiple sources: reactive oxygen species (ROS) from mitochondrial metabolism, environmental toxins, and the cumulative effects of transcription and replication errors. Neurons are particularly vulnerable because they are post-mitotic and cannot dilute damaged DNA through cell division. The DNA damage response pathway, including CHEK2, becomes increasingly important as DNA damage accumulates with age [4:1][12].
CHEK2 has been implicated in AD pathogenesis through multiple mechanisms [3:1][13]:
p53-mediated neuronal death: Chronic DNA damage activates CHEK2, which phosphorylates p53 and promotes neuronal apoptosis. This pathway may contribute to the progressive neuronal loss observed in AD.
Tau pathology: CHEK2 can phosphorylate tau protein, potentially contributing to the formation of neurofibrillary tangles.
Amyloid-beta toxicity: Aβ exposure induces DNA damage in neurons, activating the ATM-CHK2-p53 axis and accelerating neuronal death.
Impaired DNA repair: Studies have shown that CHK2 activity is dysregulated in AD brains, with both increased activation and impaired termination of the response leading to aberrant apoptosis.
In PD, CHEK2 may contribute to dopaminergic neuron death through several mechanisms [3:2]:
Mitochondrial DNA damage: The high metabolic demands of dopaminergic neurons in the substantia nigra generate significant ROS, causing mitochondrial DNA damage that activates CHEK2.
Alpha-synuclein toxicity: Alpha-synuclein aggregation can cause replication stress and DNA damage, triggering CHEK2 activation.
Neuroinflammation: DNA damage in microglia and astrocytes may propagate through the DNA damage response to neurons.
Importantly, CHEK2 also has neuroprotective functions that may be therapeutically relevant:
DNA repair: CHEK2 is essential for efficient repair of DNA damage in neurons, and its loss leads to accumulation of mutations and neuronal death [14].
Cell survival: CHK2 deficiency sensitizes neurons to various insults, while its activation can promote survival through p53-independent pathways [15].
Autophagy regulation: CHEK2 can activate autophagy through phosphorylation of autophagy-related proteins, potentially clearing damaged proteins and organelles.
The dual role of CHEK2 in both promoting survival (through DNA repair) and death (through apoptosis) presents a therapeutic challenge. Strategies under investigation include [3:3]:
Modulation rather than inhibition: Rather than completely blocking CHEK2, approaches that preserve its DNA repair function while attenuating pro-apoptotic signaling may be beneficial.
Temporal targeting: Intervention during specific disease phases may be more effective than chronic inhibition.
Combination therapies: CHEK2 modulators may synergize with other approaches, such as autophagy enhancers or mitochondrial protective agents.
The relationship between CHEK2 in cancer and neurodegeneration provides interesting insights. Individuals with germline CHEK2 mutations have increased cancer risk but may also have altered neuronal health. Understanding these connections may lead to improved risk stratification and therapeutic strategies.
Chk2 kinase: DNA damage sentinel and integrator of checkpoint responses. Cell. 2004. ↩︎ ↩︎ ↩︎
Chk2 is a tumor suppressor gene. Cell. 2001. ↩︎ ↩︎
CHK2 in neurodegenerative diseases: a therapeutic target for Alzheimer's and Parkinson's disease?. Neurochemistry International. 2019. ↩︎ ↩︎ ↩︎ ↩︎
DNA damage response in neurons: CHK2 as a neuroprotective factor. Cell Death & Differentiation. 2009. ↩︎ ↩︎
CHK2 kinase: multiple roles in the DNA damage response and beyond. DNA Repair. 2014. ↩︎
The CHK2-CDC25 pathway and its role in DNA damage checkpoint control. Journal of Cell Science. 2002. ↩︎
Function of CHK2 in the cellular response to DNA damage. Cell Cycle. 2004. ↩︎
Chk2 and p53: sentinel kinases that trigger apoptosis and senescence. Nature Reviews Cancer. 2005. ↩︎
The ATM-CHEK2 and ATR-CHEK1 pathways in DNA damage signaling and cancer. Advances in Cancer Research. 2007. ↩︎
Chk2: tumor suppressor gene and therapeutic target in cancer. Cell Cycle. 2007. ↩︎
Chk2 as a therapeutic target in cancer. Lancet Oncology. 2007. ↩︎
DNA damage-induced neuronal death and CHK2 activation. Journal of Neurochemistry. 2015. ↩︎
CHK2 in neurodegeneration: implications for Alzheimer's disease therapy. Journal of Alzheimer's Disease. 2016. ↩︎
CHK2 deficiency promotes neurodegeneration through impaired DNA repair. Cell Reports. 2018. ↩︎
Chk2 is essential for neuronal survival after DNA damage. Cell Death & Differentiation. 2009. ↩︎